Genometrix to Provide SNP-Detection Services to Agouron | GenomeWeb

NEW YORK, March 28 – Genometrix of The Woodlands, Texas, said Wednesday it had reached an agreement to provide SNP-discovery services for Agouron Pharmaceuticals, a subsidiary of Pfizer.

Genometrix did not disclose the terms of the deal, which resulted following a SNP-discovery pilot project.

Spokespeople for Genometrix and Agouron were not immediately available for comment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.